Medicare Enrolled
Dr. Barry Firstenberg, DO
Hematology & Oncology · Grapevine, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Firstenberg from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Firstenberg? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Firstenberg
Dr. Barry Firstenberg is a hematology & oncology in Grapevine, TX, with 20 years in practice. Based on federal Medicare data, Dr. Firstenberg performed 35,642 Medicare services across 2,944 unique beneficiaries.
Between the years covered by Open Payments, Dr. Firstenberg received a total of $15,955 from 71 pharmaceutical and/or device companies across 510 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Firstenberg is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 27% volume in TX$ $15,955 industry payments
Medicare Practice Summary
Medicare Utilization ↗35,642
Medicare services
Top 27% in TX for hematology & oncology
2,944
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,782 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 9,600 | $43 | $137 |
| Contrast dye for imaging (iodine-based) | 5,500 | $0 | $3 |
| Iron sucrose injection (Venofer) | 4,200 | $0 | $2 |
| Immune globulin infusion (Octagam) | 3,600 | $33 | $234 |
| Denosumab injection (Prolia/Xgeva) | 2,280 | $19 | $67 |
| Dexamethasone injection (steroid) | 1,191 | $0 | $1 |
| Comprehensive metabolic blood panel | 1,079 | $10 | $64 |
| Complete blood count (CBC) with differential | 1,072 | $8 | $36 |
| Lactate dehydrogenase (enzyme) level | 1,036 | $6 | $31 |
| Office visit, established patient (30-39 min) | 643 | $92 | $368 |
| Blood draw (venipuncture) | 624 | $8 | $20 |
| Anti-nausea injection (Aloxi/palonosetron) | 570 | $1 | $114 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 300 | $90 | $1,348 |
| Injection, granisetron hydrochloride, 100 mcg | 290 | $0 | $24 |
| Administration of chemotherapy into vein, 1 hour or less | 254 | $102 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 250 | $23 | $157 |
| Carcinoembryonic antigen (cea) protein level | 247 | $19 | $99 |
| Office visit, established patient, complex (40-54 min) | 237 | $136 | $496 |
| Injection, carboplatin, 50 mg | 192 | $2 | $300 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 191 | $4 | $33 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 130 | $49 | $313 |
| Reticulated (young) platelet measurement | 119 | $35 | $143 |
| Hospital follow-up visit, moderate complexity | 110 | $61 | $247 |
| Administration of chemotherapy into vein, each additional hour | 105 | $22 | $161 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 98 | $20 | $128 |
| Iron level test | 97 | $6 | $27 |
| Iron binding capacity test | 97 | $9 | $35 |
| Ferritin level test (iron stores) | 95 | $13 | $60 |
| Injection, diphenhydramine hcl, up to 50 mg | 93 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 90 | $51 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 89 | $15 | $100 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 86 | $91 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 84 | $1,158 | $4,802 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 80 | $285 | $2,762 |
| Microscopic examination for white blood cells with manual cell count | 74 | $4 | $22 |
| Complete blood count (CBC), automated | 74 | $6 | $34 |
| Injection of additional new drug or substance into vein | 60 | $12 | $108 |
| Ct scan of chest with contrast | 58 | $41 | $821 |
| Drug injection, under skin or into muscle | 54 | $11 | $96 |
| Hospital follow-up visit, low complexity | 51 | $39 | $135 |
| CT scan of abdomen and pelvis with contrast | 49 | $148 | $1,067 |
| Office visit, established patient (20-29 min) | 48 | $67 | $250 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 46 | $27 | $145 |
| New patient office visit, complex (60-74 min) | 46 | $159 | $709 |
| Infusion, normal saline solution , 1000 cc | 42 | $2 | $19 |
| Administration of additional new drug or substance into vein using push technique | 39 | $43 | $289 |
| Unclassified drugs | 38 | $1 | $9 |
| Uric acid level test | 36 | $4 | $25 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 34 | $333 | $1,722 |
| Infusion into a vein for hydration, each additional hour | 24 | $10 | $75 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 24 | $186 | $700 |
| Application of on-body injector for under skin injection | 23 | $15 | $96 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $57 | $211 |
| Hospital follow-up visit, high complexity | 17 | $93 | $357 |
| Manual urinalysis test with examination using microscope, non-automated | 16 | $4 | $26 |
| Initial hospital admission, high complexity | 14 | $135 | $694 |
| Nuclear medicine study whole body with ct scan | 13 | $1,156 | $4,929 |
| New patient office visit (45-59 min) | 12 | $119 | $565 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.6% high complexity
70.3% medium
18.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$15,955
Total received (2018-2024)
Avg $2,659/year across 6 years
Top 24% in TX for hematology & oncology
71
Companies
510
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,347 (83.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,596 (16.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,641
2023$867
2022$614
2021$1,047
2019$5,216
2018$6,570
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$3,018
AstraZeneca Pharmaceuticals LP
$2,871
Genentech USA, Inc.
$806
E.R. Squibb & Sons, L.L.C.
$738
Amgen Inc.
$683
PFIZER INC.
$621
Daiichi Sankyo Inc.
$485
TESARO, Inc.
$429
Janssen Biotech, Inc.
$426
Gilead Sciences, Inc.
$414
PUMA BIOTECHNOLOGY, INC.
$345
Bayer HealthCare Pharmaceuticals Inc.
$302
Incyte Corporation
$283
Janssen Scientific Affairs, LLC
$277
Exelixis Inc.
$257
Celgene Corporation
$249
TerSera Therapeutics LLC
$207
Lilly USA, LLC
$193
Adaptive Biotechnologies Corporation
$188
Astellas Pharma US Inc
$179
Merck Sharp & Dohme LLC
$171
Merck Sharp & Dohme Corporation
$165
AbbVie, Inc.
$160
ABBVIE INC.
$157
Seattle Genetics, Inc.
$145
Mirati Therapeutics, Inc.
$143
Boehringer Ingelheim Pharmaceuticals, Inc.
$140
Verastem, Inc.
$132
G1 Therapeutics, Inc.
$124
Takeda Pharmaceuticals U.S.A., Inc.
$122
GENZYME CORPORATION
$95
ADC Therapeutics America, Inc.
$94
Pharmacyclics LLC, An AbbVie Company
$93
Helsinn Therapeutics (U.S.), Inc.
$85
Ipsen Biopharmaceuticals, Inc
$81
EMD Serono, Inc.
$69
Karyopharm Therapeutics Inc.
$65
Bayer Healthcare Pharmaceuticals Inc.
$64
Puma Biotechnology, Inc.
$50
Heron Therapeutics, Inc.
$49
Alexion Pharmaceuticals, Inc.
$44
Stemline Therapeutics Inc.
$43
Kyowa Kirin, Inc.
$41
INSYS Therapeutics Inc
$40
Teva Pharmaceuticals USA, Inc.
$37
PharmaEssentia USA Corporation
$35
Rigel Pharmaceuticals, Inc.
$35
BeiGene USA, Inc.
$35
Blue Earth Diagnostics Limited
$32
MEDIVATION FIELD SOLUTIONS LLC
$31
Pharmacosmos Therapeutics Inc.
$30
CTI BioPharma Corp.
$28
Deciphera Pharmaceuticals Inc.
$26
Regeneron Healthcare Solutions, Inc.
$26
SOBI, INC
$26
Eisai Inc.
$22
JAZZ PHARMACEUTICALS INC.
$22
Coherus Biosciences Inc.
$22
ARRAY BIOPHARMA INC
$22
Immunocore Limited
$19
Sirtex Medical Inc
$19
Array BioPharma Inc.
$18
Agios Pharmaceuticals, Inc.
$18
GlaxoSmithKline, LLC.
$16
Clovis Oncology, Inc.
$15
BTG International, Inc.
$15
Novocure Inc.
$13
Genmab U.S., Inc.
$13
Johnson & Johnson Vision Care, Inc.
$13
Taiho Oncology, Inc.
$13
Seagen Inc.
$13
Top 3 companies account for 42.0% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · Abraxane · Acuvue · Alecensa · Aliqopa · Avastin · Axumin · BENDEKA · BESPONSA · BESREMI · BOSULIF · BRUKINSA · Bavencio · Braftovi · CALQUENCE · CINVANTI · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DAURISMO · DOPTELET · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Epkinly · Erleada · Fabhalta · GAZYVA · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Idhifa · Imbruvica · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OPDIVO · OPDUALAG · Oncology · Orserdu · PADCEV · PLUVICTO · PROMACTA · PYRUKYND · Perjeta · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SIR-Spheres Microspheres · SPRYCEL · SUSTOL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VORAXAZE · VOTRIENT · Venclexta · Vitrakvi · Vonjo · XALKORI · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $45 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
153
Per 100K population
7.2
County median income
$81,905
Nearest hospital
BAYLOR SCOTT & WHITE MEDICAL CENTER GRAPEVINE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Firstenberg is a mixed practice specialist, with above-average Medicare volume (top 27% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Firstenberg experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Firstenberg performed 9,600 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Firstenberg receive payments from pharmaceutical companies?
Yes. Dr. Firstenberg received a total of $15,955 from 71 companies across 510 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Firstenberg's costs compare to other hematology & oncologys in Grapevine?
Dr. Firstenberg's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Firstenberg) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Grapevine
Browse hematology & oncologys in Grapevine ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology